Distinguished in Immune Thrombocytopenic Purpura (ITP)

Dr. Catherine Broome

Hematology
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Catherine Broome is a Hematologist in Washington, Washington, D.c.. Dr. Broome is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Autoimmune Hemolytic Anemia, Chronic B-Cell Leukemia (CBCL), Thrombocytopenia, Bone Marrow Aspiration, and Splenectomy.

Her clinical research consists of co-authoring 36 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 1 clinical trial in the study of Immune Thrombocytopenic Purpura (ITP).

Specialties
Hematology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (LUMINA 2)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rilzabrutinib
Study Phase: Phase 2
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Biological
Study Drugs: Thrombosomes, Liquid-Stored Platelets
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Enrollment Status: Completed
Publish Date: May 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

36 Total Publications

Dual therapy: danicopan as add-on therapy to C5 inhibitors.
Dual therapy: danicopan as add-on therapy to C5 inhibitors.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Similar Doctors
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (0.1 miles away)
202-444-3700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Craig Kessler is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Kessler is rated as an Elite provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy. Dr. Kessler is currently accepting new patients.

Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Ralph V. Boccia
Hematology Oncology | Oncology | Hematology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. Ralph V. Boccia
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
 (8.4 miles away)
301-571-0019
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ralph Boccia is a Hematologist Oncology specialist and an Oncologist in Bethesda, Maryland. Dr. Boccia is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Bone Tumor, Anemia, Iron Deficiency Anemia, Multiple Myeloma, and Splenectomy. Dr. Boccia is currently accepting new patients.

Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. David Smith
Hematology | Oncology
Distinguished in Immune Thrombocytopenic Purpura (ITP)
Dr. David Smith
Hematology | Oncology

American Oncology Partners PA

8221 Teal Dr, Suite 302, 
Easton, MD 
 (55.8 miles away)
410-820-5945
Languages Spoken:
English
See accepted insurances

David Smith is a Hematologist and an Oncologist in Easton, Maryland. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Myelodysplastic Syndrome (MDS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Broome's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 19 Advanced Conditions
View All 82 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile